Literature DB >> 1864220

Hyperinsulinemia or increased sympathetic drive as links for obesity and hypertension.

M Modan1, H Halkin.   

Abstract

The association of obesity with hypertension has been amply demonstrated in cross-sectional, longitudinal, and dietary-intervention studies, but the mechanisms remain enigmatic. Both conditions are independently characterized by similar metabolic alterations, i.e., glucose intolerance, dyslipoproteinemia, elevated serum uric acid, and inadequate Na+ transport. Obesity, hypertension, and these metabolic alterations are associated with hyperinsulinemia/insulin resistance. The degree of these alterations is lowest in lean hypertensives, intermediate in obese normotensives, and greatest in obese hypertensives, but mortality risk is highest in lean hypertensives. This apparent discrepancy may be related to the divergent hemodynamic characteristics, possibly indicating different etiology, of lean and obese hypertensives, i.e., contracted blood volume, increased total vascular peripheral resistance, and normal sympathetic drive in the former, expanded blood volume, normal peripheral resistance, and increased sympathetic drive in the latter. Current knowledge suggests that the interrelationships of obesity and hypertension with the metabolic alterations could be mediated by high carbohydrate and fat consumption and low physical activity, resulting in obesity and separate pathways in hyperinsulinemia and increased sympathetic drive, leading to a double vicious cycle. In one, hyperinsulinemia and the consequent insulin resistance would compound one another. In the second, the increasing hyperinsulinemia would increasingly stimulate the sympathetic nervous system. This double vicious cycle could result in increasing hemodynamic and metabolic derangements causing hypertension, diabetes, and atherosclerotic cardiovascular disease (ASCVD). The association of lean hypertension with ASCVD may be through other mechanisms, e.g., hemodynamic forces on the vascular endothelium.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1864220     DOI: 10.2337/diacare.14.6.470

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  11 in total

Review 1.  Serum uric acid is not an independent risk factor for coronary heart disease.

Authors:  S G Wannamethee
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

Review 2.  Body fat and sympathetic nerve activity.

Authors:  U Scherrer; R Owlya; M Lepori
Journal:  Cardiovasc Drugs Ther       Date:  1996-06       Impact factor: 3.727

3.  Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans.

Authors:  P Vollenweider; D Randin; L Tappy; E Jéquier; P Nicod; U Scherrer
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

4.  Multiple lipolysis defects in the insulin resistance (metabolic) syndrome.

Authors:  S Reynisdottir; K Ellerfeldt; H Wahrenberg; H Lithell; P Arner
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

Review 5.  Perturbed autonomic nervous system function in metabolic syndrome.

Authors:  Nicholas Tentolouris; Georgia Argyrakopoulou; Nicholas Katsilambros
Journal:  Neuromolecular Med       Date:  2008-01-26       Impact factor: 3.843

6.  Adenosine actions are preserved in corpus cavernosum from obese and type II diabetic db/db mouse.

Authors:  Fernando Silva Carneiro; Fernanda R C Giachini; Victor V Lima; Zidonia N Carneiro; Romulo Leite; Edward W Inscho; Rita C Tostes; R Clinton Webb
Journal:  J Sex Med       Date:  2008-01-21       Impact factor: 3.802

Review 7.  Epidemiology of high blood pressure and obesity.

Authors:  F J Martínez; J M Sancho-Rof
Journal:  Drugs       Date:  1993       Impact factor: 9.546

8.  The influence of dairy products on plasma uric acid in women.

Authors:  P Ghadirian; B Shatenstein; M Verdy; P Hamet
Journal:  Eur J Epidemiol       Date:  1995-06       Impact factor: 8.082

Review 9.  Does the sympathetic nervous system contribute to the pathophysiology of metabolic syndrome?

Authors:  Marina C Dos Santos Moreira; Izabella S de Jesus Pinto; Aline A Mourão; James O Fajemiroye; Eduardo Colombari; Ângela A da Silva Reis; André H Freiria-Oliveira; Marcos L Ferreira-Neto; Gustavo R Pedrino
Journal:  Front Physiol       Date:  2015-08-25       Impact factor: 4.566

Review 10.  Clusterin and Its Role in Insulin Resistance and the Cardiometabolic Syndrome.

Authors:  Jennifer Wittwer; David Bradley
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.